Pacira BioSciences Inc. (PCRX)
Market Open
19 Oct, 05:54 PM
$
36. 36
+0.02
+0.055%
$
1.45B Market Cap
215.33 P/E Ratio
- Div Yield
379,325 Volume
3.01 Eps
$ 36.34
Previous Close 
Want to track PCRX and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Should Value Investors Buy Pacira BioSciences (PCRX) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks | 2 years ago
Pacira (PCRX) Rises on Proposed Exparel Reimbursement Plan
Pacira (PCRX) gains upon the inclusion of Exparel as one of only six qualifying non-opioid drugs to treat postsurgical pain in the proposed reimbursement rule, if adopted.
Zacks | 2 years ago
Why Is Pacira (PCRX) Up 1.7% Since Last Earnings Report?
Pacira (PCRX) reported earnings 30 days ago. What's next for the stock?
Zacks | 2 years ago
2026 © Marketlog. All Rights Reserved.
